The addition of the novel heparan sulfate (HS) mimetic PG545 to standard chemotherapy shows promising efficacy in the treatment of ovarian cancer in vitro and in vivo by Freyer, Luisa
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Figure! 2:! Percent! (%)! cellular! viability! of! ovarian! cancer! cell! lines,! A2780! and!SKOV3,!treated!with!increasing!concentrations!of!PG545!for!48!hours.!………..……29!










Figure! 13:! Representative! staining! of! CD31! of! blood! microvessels! of! A2780!xenografts!in!mice!at!time!of!autopsy…………..……………………………………………………46!






3.1 Ovarian!Cancer!!With!an!estimated!22,440!new!cases!in!the!United!States!in!2017,!ovarian!cancer!is!the! second! most! common! gynecologic! cancer! (Cancer! Facts! &! Figures! 2017).!“Epithelial!ovarian!cancer!(EOC)!is!the!fifth!leading!cause!of!cancer!deaths!among!women!in!the!United!States”!(FleskenLNikitin,!Hwang!et!al.!2013)!and!with!15,500!estimated! deaths! per! year! it! is! the! most! lethal! gynecologic! cancer! (Siegel,!Naishadham!et!al.!2012).!!The! highly! lethal! nature! of! this! cancer! stems! from! its! asymptomatic! growth,!resulting! in! advanced,!widespread! disease! in! about! 70%! of!women! at! diagnosis!(Yoneda,!Lendorf!et!al.!2012).!!The!current!treatment!for!women!with!newly!diagnosed!advanced!ovarian!cancer!is,!surgical!cytoreduction!followed!by!platinum!and!taxaneL!based!chemotherapy,!which!results!in!complete!clinical!remission!(CCR)!in!up!to!75%!of!cases!(Mei,!Chen!et!al.!2013).!However,!75%!of!the!responders!will!relapse!within!18!to!28!months!(Mei,!Chen!et!al.!2013).!The!disease!is!no!longer!curable!at!recurrence!due!to!the!lack!of!effective!therapies!resulting!in!only!30%!5!year!survival!of!advanced!stages!(Naora!and!Montell!2005).!!“!The!average!lifetime!risk!for!women!is!about!1!in!70”!(Cannistra!2004)!and!with!a!median!age!of!60,!the!disease!predominantly!affects!postmenopausal!women!(Liu!2005).!Most!ovarian!cancers!result!from!sporadic!mutations!(Yoneda,!Lendorf!et!al.!2012).! Although! only! around! 10! percent! of! ovarian! cancer! patients! have! an!identifiable! genetic! predisposition,! the! most! important! risk! factor! of! ovarian!cancer!is!a!family!history!of!ovarian!or!breast!cancer!(Cannistra!2004).!Moreover,!there! is!a!general!agreement!that!nullparity,!early!menarche!and! late!menopause!are!associated!with!an!elevated!risk!of!ovarian!cancer!and!that!oral!contraceptive!use,! pregnancy,! and! lactation! are! associated! with! a! reduced! risk! (Whittemore!1994,! Cannistra! 2004).! These! findings! propose! that! repeated! stimulation! of! the!epithelium! of! the! ovarian! surface,! as! a! result! of! a! high! number! of! lifetime!
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ovulations,!may!predispose!the!epithelium!to!malignant!transformation!(Cannistra!2004,!Liu!2005).!!Epithelial! ovarian! cancer,! also! ovarian! carcinoma,! is! the! most! common! type! of!ovarian! cancer! (Schildkraut,! Iversen! et! al.! 2013).! Of! the! five! main! subtypes! of!ovarian! carcinoma! (high! grade! serous,! endometrioid,! clear! cell,! mucinous! and!undifferentiated),!highL!grade!serous!epithelial!ovarian!cancer!is!the!most!common!(Schildkraut,!Iversen!et!al.!2013)!and!most!lethal!(Kessler,!Fotopoulou!et!al.!2013)!and!characterized!by!its!chromosomal!instability!(Wang,!Birkbak!et!al.!2012).!!!
3.1.1 Metastasis*in*ovarian*cancer*!As! the!majority!of!patients!present! at! an!advanced! stage,!with!widely!metastatic!spread!within!the!peritoneal!cavity,!metastasis!plays!an!important!role!in!ovarian!cancer.! In! contrast! to! hematogenously! metastasizing! tumors,! ovarian! cancer!metastasizes!either!by!direct!extension!to!neighboring!organs!or!when!cancer!cells!detach! from! the! primary! tumor! (Lengyel! 2010).! This! process! is! facilitated! by!enzymes,!like!heparanase,!that!disconnect!intercellular!adhesions,!loosen!the!ECM!(extracellular!matrix)!and!lead!to!shedding!of!single!cells!from!the!primary!tumor!(Vlodavsky!and!Friedmann!2001).!Then,! transported! throughout! the!peritoneum!by! normal! peritoneal! fluid,! exfoliated! tumor! cells! spread! within! the! abdominal!cavity! (Lengyel! 2010).! ! The! dissemination! of! tumors! cells! within! the! peritoneal!cavity! is! often! associated! with! the! production! of! ascites! (Gavalas,! Liontos! et! al.!2013).! Carried!by! the!peritoneal! fluid,! cancer! cells! have! to! overcome!anoikis,! an!intrinsically!programmed!cell!death!(apoptosis)!that!occurs!due!to!detachment!of!a!cancer! cell! from! the! extracellular! matrix! (Kandala! and! Srivastava! 2012).!Resistance! to! anoikis! is! an! essential! feature! of! a! metastasizing! tumor! cell! and!contributes!to!the!formation!of!metastasis!in!other!organs!(Kandala!and!Srivastava!2012).!After!overcoming!anoikis!and!circulating!in!the!peritoneal!fluid,!cancer!cells!attach,!preferentially!on! the!abdominal!peritoneum!or!omentum!(Lengyel!2010).!The!viability!of! these!cells!and!successful! tumor!formation!on!a!metastatic!site! is!further!dependent!upon!the!development!of!sufficient!neovasculature!(Jelovac!and!Armstrong!2011)!through!neoangiogenesis.!
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3.1.2 Angiogenesis*in*ovarian*cancer*!Angiogenesis! is! defined! as! the! growth! and! recruitment! of! new! blood! vessels!(Nadkarni,!Geest!et! al.!2013).! It! is! a! complex!and!highly! regulated!process!and!a!key!factor!for!tumor!progression!and!development!of!metastasis!(Spannuth,!Sood!et! al.! 2008).! Tumor! growth! beyond! a! few! millimeters! is! dependent! on!angiogenesis,! as! the! production! of! new! blood! vessels! is! necessary! to! supply! the!tumor!with!oxygen!and!nutrients!(Teodoro,!Evans!et!al.!2007).!!Angiogenesis! is! a! multiLstep! process! (Martin! and! Schilder! 2007),! which! is!regulated!by!a!balance!between!proangiogenic!and!antiangiogenic!molecules!such!as!cytokines!and!proangiogenic!growth!factors!(i.e.!VEGF,!plateletLderived!growth!factor,! fibroblast! growth! factor).! ! In! tumors! this! equilibrium! is! altered,! balance!leans!“towards!the!greater!expression!of!proLangiogenic!factors!and!angiogenesis!occurs”!(Gavalas,!Liontos!et!al.!2013).!Markers!of!angiogenesis!such!as!VEGF!and!CD31! have! been! identified! to! have! prognostic! value! in! ovarian! cancer! patients!(Nadkarni,! Geest! et! al.! 2013)! and! increased! vascularity! is! associated! with! poor!survival! in! patients! with! ovarian! carcinoma! (Alvarez,! Krigman! et! al.! 1999).!Furthermore,!with!a!strong!expression!in!ovarian!carcinoma,!moderate!expression!in!borderline!tumors!and!a!weak!or!no!expression!in!normal!ovarian!tissue,!VEGF!expression!is!cancer!specific!(Schmitt!and!Matei!2012).!!Angiogenesis! also! contributes! to! the! metastatic! process! (Folkman! 1990).!Neovascularization! permits! the! dissociation! of! cells! from! the! primary! tumor!(Folkman! 1990).! It! was! also! shown! that! VEGF! overexpression! may! lead! to!peritoneal! related! neoangiogenesis! and! increased! vascular! permeability! in! the!peritoneum,!suggesting!that!angiogenesis!is!involved!in!the!metastasis!of!tumor!to!the! peritoneum! (Gavalas,! Liontos! et! al.! 2013).! A! decrease! of! angiogenesis! is!associated! with! a! decreased! rate! of! metastasis! (Folkman! 1990).! ! The!understanding! of! the! molecular! mechanisms! of! tumor! angiogenesis! led! to! the!identification!of!angiogenic!targets!and!the!development!of!antiLvascular!agents.!!!
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3.1.3 Heparan*sulfates*and*heparanase*in*ovarian*cancer*!Due!to!the!inherent!instability!of!the!genome!of!highL!grade!serous!ovarian!cancer,!the!focus!of!current!research!has!shifted!from!the!tumor!itself,!to!a!new!target:!the!tumor! microenvironment! (Vaughan,! Coward! et! al.! 2011).! According! to! Paget’s!‘seed! and! soil’! hypothesis,! which! is! now! widely! accepted,! a! cancer’s! unique!microenvironment! and! as! part! of! it! the! extracellular! matrix! (ECM),! present! the!‘soil’! on!which! ‘the! seed’! (the! tumor! cell)! can! grow,! proliferate! and!metastasize!(Talmadge!and!Fidler!2010).!!A! key! component! of! the! ECM! is! the! ubiquitous! macromolecule! heparan! sulfate!proteoglycan!(HSPG)!(Sasisekharan,!Shriver!et!al.!2002).!The!HS!(heparan!sulfate)!chains!of!HSPGs,!which!are!attached! to!core!proteoglycans!(Joyce,!Freeman!et!al.!2005),! are! structurally! heterogeneous! and! provide! bindingLsites! for! a! diverse!repertoire!of!heparinL!binding!proteins,!including!extracellular!signaling!molecules!such!as!the!growth!factors!(for!example!FGF,!VEGF165!and!HBLEGF),!chemokines,!morphogens!and!enzymes!(Bernfield,!Gotte!et!al.!1999).!Moreover,!HSPGs!function!as!key!coLreceptors!for!these!ligands!and!thus!play!an!important!role!in!modulating!heparinLbinding!growth! factor! signaling! (Blackhall,!Merry! et! al.! 2001).!As!HSPGs!also!bind!to!structural!proteins!of!the!extracellular!matrix,!they!are!part!of!cellLcell!and! cellLmatrix! adhesion! complexes! (Davies,! Blackhall! et! al.! 2004)! and! thereby!contribute! significantly! to! the! integrity! of! the! ECM.! By! mediating! adhesion,!migration! and! cellular! responses! to! mitogenic! and! angiogenic! growth! factors,!HSPGs! regulate! multiple! pathways! including! those! important! in! tumorigenesis!such!as!tumor!progression,!angiogenesis,!and!metastasis!(Sasisekharan,!Shriver!et!al.!2002).!!!Regulation! of! HSPGs! can! occur! through! the! enzyme! heparanase,! “which! cleaves!heparan!sulfate!(HS)!and!hence!participates!in!degradation!and!remodeling!of!the!extracellular! matrix! (ECM)”! (Ilan,! Elkin! et! al.! 2006)! and! release! of! HSL! bound!biological!mediators.! It! has! been! shown! that! ovarian! carcinomas! express! higher!levels!of!heparanase!than!normal!ovaries!and!borderline!tumors!(Ginath,!Menczer!et! al.! 2001)! and! that! heparanase! is! highly! expressed! in! carcinomas! with! large!
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ascites!and!high!grade!(Kodama,!Shinyo!et!al.!2003),!suggesting!an!important!role!of!this!molecule!in!aggressive!ovarian!neoplams.!!By!cleaving!HS!chains,!resulting!in!the!degradation!of!the!ECM!and!the!loosening!of!intercellular! connections,! heparanase! promotes! cellular! mobility! and! cell!dissemination.! Consequently,! “the! expression! of! heparanase! correlates! with! the!metastatic!potential!of! tumor!cells”! (Vlodavsky!and!Friedmann!2001).! In!ovarian!carcinoma,! it! has! been! shown! that! heparanase! is! frequently! expressed! in!metastatic!ovarian!cancer,!it!is!secreted!into!the!peritoneal!fluid!and!that!increased!heparanase!expression!correlates!with!poor!overall! survival! (Davidson,! Shafat! et!al.!2007).!!By! degrading! HS! in! the! subLendothelial! basement! membrane! of! blood! vessels,!heparanase! facilitates!endothelial! cell!migration!and!sprouting,!which! is!an!early!event! in! the! angiogenic! process.!Moreover,! the! release! of! HSL! bound! angiogenic!growth!factors!(bFGF,!VEGF)!through!heparanase!activity!liberates!proLangiogenic!molecules! that!may! act! cooperatively! to! promote! neovascularization! (Vlodavsky!and! Friedmann! 2001).! Therefore! it! is! not! surprising,! that! increased! heparanase!expression! is!associated!with! increased!microvessel!density!(Vlodavsky,!AbboudLJarrous! et! al.! 2006).! Targeting! heparanase! thus! presents! a! promising! target! to!mediate!antiLangiogenic!and!antiLmetastatic!effects.!!
3.2 Therapy!of!ovarian!cancer!!The!standard!therapy!of!ovarian!cancer!consists!of!primary!cytoreductive!surgery!followed!by!platinumL!based!chemotherapy.!The!amount!of!residual! tumor! is! the!most! important! prognostic! survival! factor! of! ovarian! cancer! patients! (Elattar,!Bryant! et! al.! 2011),! the! surgical! treatment! is! aggressive! and! the! goal! of!cytoreductive!surgery!is!optimal!debulking,!which!means!no!residual!tumor!<!1cm.!More! recently! optimal! debulking! is! considered! as! no! residual! tumor! (R0).! The!surgical! goal! is! a! complete! cytoreduction! with! no! residual! after! surgery.!Nevertheless,! surgical! cytoreduction! is,! due! to! the! cancer’s! diffuse! nature,! rarely!sufficient! to! render!patients!diseaseLfree!and!adjuvant! chemotherapy! is! required!
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to! eradicate! residual! disease,! except! for! women!with! organLconfined,! lowLgrade!disease!(Naora!and!Montell!2005).!!The! current! standard! chemotherapy! for! advanced! ovarian! cancer! is! the!intravenous! administration! of! six! cycles! of! carboplatin! and! paclitaxel.! Platinum!based! compounds,! such! as! carboplatin! and! cisplatin,! are! the! most! potent!chemotherapeutics! in! ovarian! cancer! treatment! (Cannistra! 2004).! They!mediate!their!effect! through!the! formation!of! intrastrand!crossLlinks!with!DNA!(Cannistra!2004).! Taxanes,! for! example! paclitaxel,! exert! their! cytotoxic! effects! through!binding! to! and! stabilization! of! tubulin! polymers! (Cannistra! 2004).! As! ovarian!cancer!is!highly!sensitive!to!chemotherapy,!the!majority!of!patients!will!achieve!a!full!remission!with!initial!treatment!(Jelovac!and!Armstrong!2011).!It!is!commonly!acknowledged! that! a! platinum! and! taxaneLbased! chemotherapy! improves! both,!progressionLfree!survival!(PFS)!and!overallL!survival!(OS)!(Binaschi,!Simonelli!et!al.!2011).!!!Despite! an! initial! response! in! about! 80%! of! patients,! relapse! occurs! in! most!patients!with!advancedLstage!disease,!making!ovarian!cancer!essentially!incurable!(Jelovac!and!Armstrong!2011).!Although!recurrent!cancer!is!highly!treatable,!it!has!a! very! poor! prognosis.! Patients! have! to! receive! multiple! lines! of! chemotherapy!with! unsatisfactory! results!with! regard! to! PFS! and!OS,! due! to! the! occurrence! of!drug! resistant! cancer! clones! (Tomao,! Papa! et! al.! 2013).! A! large! number! of!chemotherapeutics!(liposomal!doxorubicin,!topotecan,!gemcitabine,!paclitaxel,!oral!etoposide!and!vinorelbine!(Cannistra!2004))!have!been!tested!and!can!be!used!as!secondLline! therapeutics! to! treat! (even!platinumLresistant)! recurrent! cancer,! but!the!second!remission!is! in!more!than!95%!of!cases!shorter!than!the!first!(Jelovac!and!Armstrong!2011)! resulting! in!a!median!survival!of! less! than! two!years! from!the!time!of!recurrence!(Gadducci,!Cosio!et!al.!2005).!!!
3.2.1 Maintenance*therapy,*recurrence*and*cancer*stem*cells*(CSC)*!As!recurrence!of!chemoLresistant!ovarian!cancer!after!initial!response!to!firstLline!chemotherapy! is! the! major! obstacle! in! the! treatment! of! ovarian! cancer,! one!
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potential! strategy! that! may! improve! patient! outcome! is! maintenance! therapy!targeting!residual!subclinical!disease.!Strategies!of!maintenance!therapy!aiming!to!impede! recurrence! and! to! prolong! progressionLfree! survival! (PFS)! have! been!studied,!but!a!statistically!significant!prolongation!of!PFS!has!only!been!achieved!by!prolonged!administration!of!paclitaxel!and!the!combination!of!bevacizumab!and!chemotherapy! followed!by!a!maintenance!period!of!bevacizumab!(12L!15!cycles)!(Binaschi,!Simonelli!et!al.!2011).!Clearly,! disease! recurrence! is! caused! by! persisting! dormant! and! drugLresistant!cells!after!frontLline!therapy!(Binaschi,!Simonelli!et!al.!2011).!“Recent!studies!have!identified! and! characterized! a! selfLrenewing! subpopulation! of! cancerLinitiating!cells! in!ovarian!cancers!endowed!with!stem!cellLlike!properties”!(Siu,!Wong!et!al.!2013).!These!cancerLinitiating!cells,!also!called!cancer!stem!cells,!have!the!ability!to!selfLrenew,!differentiate!and!to! form!tumors!(Zhan,!Wang!et!al.!2013).!Moreover,!cancer!stem!cells!have!been!reported! to!be! involved! in!drug!resistance!and!have!been! identified! as! key! players! in! the! development! of! recurrence.! “Traditional!chemotherapy! can! kill! the!majority! of! cancer! cells,!while! failing! to! target! cancer!stem!cells”!(Zhan,!Wang!et!al.!2013).!These!cells!survive!chemotherapy!and!enter!a!state!of!dormancy!during!which! they!survive! in! still!undefined!niches!within! the!body!before!being!stimulated!to!initiate!reLgrowth!(Binaschi,!Simonelli!et!al.!2011).!Recent!studies,!showing!that!cisplatin!treatment!of!ovarian!cancer!cell!lines!in#vitro!leaves!residual!cells!that!are!enriched!in!cancer!stem!cellLlike!traits,!underline!the!importance!of!cancerLinitiating!cells! in!disease!recurrence!(Abubaker,!Latifi!et!al.!2013).!The! identification!of!cancerLinitiating!cells!“has!opened!up!a!novel! field!of!research! aimed! at! identifying! additional! innovative! therapeutic! approaches”!(Binaschi,!Simonelli!et!al.!2011).!!!
3.2.2 Targeted*therapies*!Despite!intensive!research!on!chemotherapeutic!drugs!and!the!significant!progress!made! in! understanding! the! molecular! pathogenesis! and! signaling! pathways! of!epithelial!ovarian!cancer,!this!has!not!led!to!satisfactory!improvement!in!outcomes!or!overall!survival!(Howlader!et!al.!2011;!Jelovac!et!al.!2011).!!
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Fig.1:!The!mechanism!of!action!of!PG545.!!Figure!provided!by!Progen.!!Aiming!attention!at!HSPGs!and!heparanase!in!the!development!of!potential!cancer!therapeutics! led! to! the! identification! of! sulfated! oligosaccharides! as! structural!mimetics! of! heparan! sulfate! with! a! dual! mechanism! of! action:! inhibition! of!“angiogenesis! by! sequestering! angiogenic! growth! factors! in! the! extracellular!matrix!(ECM),!thus!limiting!subsequent!binding!to!receptors”!(Dredge,!Hammond!et! al.! 2011)! and! inhibition! of! metastasis! by! inhibiting! heparanase,! the! only!endglycosidase,!which!cleaves!HS!chains!in!the!ECM.!The!hypothesis!was! that!HS!mimetics,! targeting!heparanase!and!multiple!growth!factors! in! the! tumor!microenvironment,!would! function! as! inhibitors! of!multiple!signaling! pathways,! resulting! in! inhibition! of! tumor! growth,! angiogenesis! and!metastatic!spread.!A!heparan!sulfate!mimetic!of!the!first!generation,!which!had!the!important!property! of! simultaneously! inhibiting! angiogenesis! and!heparanase,! is!PIL88!(Parish,!Freeman!et!al.!1999,!Joyce,!Freeman!et!al.!2005,!Ferro,!Dredge!et!al.!2007).!Seeking! to! improve!upon! the! functionality!of!PIL88,! the!PG500!series!was!born!and!PG545!was!identified!as!the!leading!compound!for!further!investigation!as!a!novel!antiLcancer!agent!(Dredge,!Hammond!et!al.!2010).!!
Introduction!_______________________________________________________________________________________________!
!15!
“PG545!is!a!fully!sulfated!tetrasaccharide!functionalized!with!a!cholestanyl!aglycon!designed! at! Progen! Pharmaceuticals! Ltd! (Brisbane,! QLD,! Australia)”! (Dredge,!Hammond! et! al.! 2011).! Compared! to! PIL88,! increased! potency! and! lower!anticoagulant! property! was! achieved! by! adding! a! lipophilic! moiety! (aglycon)!(Ferro,! Liu! et! al.! 2012).! Testing! for! HSLbinding! site! activity! indicated! low!nanomolar! binding! of! PG545! to! HSL! binding! proteins,! which! are! important! in!tumor! angiogenesis! such! as! FGF1,! FGF2! and! VEGF! and! potent! inhibition! of!heparanase! (Ki=! 6! nM)! (Dredge,! Hammond! et! al.! 2010).! In! cellLbased! assays,!PG545! potently! inhibited! growth! factorLinduced! endothelial! cell! proliferation,!which! is! the! first!essential!cellular!step! in!angiogenesis! (Dredge,!Hammond!et!al.!2010).!In!an!ex#vivo!rat!aortic!ring!assay,!PG545!had!an!over!80%!inhibitory!effect!on!angiogenesis!(Dredge,!Hammond!et!al.!2010).!!
In# vivo,! PG545! was! shown! to! inhibit! angiogenesis! and! solid! tumor! growth! in!murine!mouse!models!of!multiple!types!of!cancer!(Ferro,!Liu!et!al.!2012).!The!antiLmetastatic! activity! of! PG545!was! tested! in! three!murine!models! of!metastasis:! a!B16! melanoma! model,! a! HTL29! colon! carcinoma! model! and! a! Lewis! Lung!Carcinoma!model,! in!all!of!which!PG545!significantly! inhibited!metastatic!spread,!resulting!in!a!reduced!number!of!metastasis!(Dredge,!Hammond!et!al.!2011).!In! ovarian! cancer,! it! has! been! shown! recently,! that! independent! of! the! heparinL!binding! growth! factor! (HBLEGF,! HGF,! FGFL2,! VEGF! or! SDFL1)! used! to! stimulate!SKOV3L!ovarian!cancer!cells,!the!exposure!to!PG545!reduced!cellular!migration!and!invasive! capacity.! The! theory,! that! PG545,! by! inhibiting! heparanase! and!sequestering! growth! factors,! attenuates! downstream! cell! signaling,! has! been!confirmed!by!the!finding!that!treatment!of!SKOV3!and!OV202!ovarian!cancer!cells!with! PG545! results! in! decreased! activation! of! the! EGF! receptor! and! subsequent!decreased! phosphorylation! of! the! downstream! signaling! proteins! of! the! ERK/!MAPK! pathway! in# vitro.! Furthermore,! PG545! showed! significant! antiLtumor!activity! with!marked! reduction! in! tumor! burden! in! cisplatinLsensitive,! cisplatinL!resistant! and! immunocompetent! ovarian! tumor!mouse!models! in#vivo! as! both,! a!single! agent! and! in! combination! with! the! standard! chemotherapeutics! cisplatin!and! paclitaxel.! The! antiLmetastatic! effect! of! PG545! in! ovarian! cancer! has! been!studied!in#vitro!and!in#vivo.!PG545!was!found!to!inhibit!adhesion!of!ovarian!cancer!
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cells! to!mesothelial! cells! in#vitro#and!significantly! inhibited!bowel! and!peritoneal!dissemination!in!a!highly!metastatic!in#vivo!tumor!model!(data!not!published).!PG545! is! currently!being! investigated! in!a!Phase! I! clinical! trial! in!advanced!solid!cancer!patients!(Winterhoff,!Freyer!et!al.!2015).!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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4 Aim!of!the!study!!Despite! significant! progress! in! understanding! the! nature! of! ovarian! cancer! and!considerable! advances! in! cytotoxic! therapy,! the! overall! 5Lyear! survival! rate! in!patients!suffering!from!ovarian!cancer!remains!at!30%.!This!is!mainly!attributed!to!recurrence!of!the!disease!after!initial!response!to!surgical!treatment!and!firstLline!chemotherapy.! Currently! there! is! no! drug! or! drug! combination! available! that!effectively! eradicates! remaining! cancer! cells! after! surgery! and! thus! prevents!recurrence! of! the! disease.! The! novel! heparanLsulfate!mimetic! PG545! has! shown!promising!results!as!an!antiL!cancer!drug!in#vitro!and!in#vivo.!PG545!provides,!next!to! formation! of! intrastrand! crossLlinks! with! DNA! by! cisplatin! and! binding! to!tubulin!polymers!by!taxanes,!a!third!mechanism!of!action!to!attack!ovarian!cancer!cells! and! thus! seems! to! be! a! promising! addition! to! conventional! chemotherapy.!Furthermore,! due! to! the! characteristic! overexpression! of! VEGF! (vascular!endothelial! growth! factor),! a! growth! factor! promoting! angiogenesis,! in! 90%! of!human!ovarian!tumors!and!the!high!metastatic!potential!of!this!disease,!epithelial!ovarian!cancer!provides!an!ideal!target!for!PG545.!!The! principal! aim! of! this! study! is! to! test! if! the! addition! of! PG545! to! standard!chemotherapy!with!cisplatin!and!paclitaxel!provides!a!more!powerful!antiLcancer!regimen.! We! also! seek! to! identify! the! most! effective! schedule! of! drug!administration!and!examine!if!the!addition!of!PG545!to!standard!chemotherapy!is!effective! in! preventing! recurrence! of! ovarian! cancer! in! a!maintenance! setting! in#
vivo.!!First,! the! effect! of! PG545! on! A2780! and! SKOV3! ovarian! cancer! cells! as! a! single!agent!and!in!combination!with!the!standard!chemotherapeutics!for!ovarian!cancer,!cisplatin! and! paclitaxel,! is! investigated! in# vitro.! As! PG545! has! previously! shown!antiLmetastatic! potential,! the! effect! of! PG545,! alone! and! in! combination! with!cisplatin,!on!ovarian!cancer!cells!growing!under!detachment!growth!conditions!is!examined!in#vitro.!!Next,! the! antiLtumor! effect! of! PG545! is! tested! in! an! in# vivo! model! for! recurrent!ovarian!cancer.!We!investigate!the!efficacy!of!PG545!in!combination!with!standard!chemotherapy! and! as! a!maintenance! agent! and! test,! if! the! addition! of! PG545! to!
Material!and!Methods!_______________________________________________________________________________________________!
!18!

































































GAPDH,!rabbit,!monoclonal! Cell!Signaling!Technology,!Danvers,!MA,!USA!CD31,!mouse,!monoclonal! PECAM,! Santa! Cruz! Biotechnology,! Dallas,! TX,!USA!Ki67,!rabbit,!monoclonal! Clone!EP5,!Epitomics,!Burlingame,!CA,!USA!
5.1.7 Drugs*and*chemotherapeutics*
5.1.8 *Mouse*model*50! sixLweek! old,! female,! athymic! nude! mice! were! obtained! from! the! National!Cancer!Institute!(Frederick,!MD).!!
5.2 Methods!
5.2.1 Cell*culture*!Maintenance!of!cell!lines!A2780!and!A2780Lluci!cells!were!cultured!in!RPMI!1640!with!LLGlutamine!medium!supplemented!with!10%!fetale!bovine!serum!(FBS),!100! IU!penicillin,!100!µg/ml!streptomycin!and!0.01mg/ml!human!insulin!and!SKOVL3!were!cultured!in!McCoy’s!5A!with!LLGlutamine!medium!supplemented!with!10%!FBS,!100!IU!penicillin!and!100!µg/ml!streptomycin.!Cells! were! grown! in! 150cm²! tissue! culture! flasks! and!maintained! in! humidified!incubators!at!37°C!circulated!with!5%!CO2/95%!air.!Cells!were!passaged!every!3!days.!!






Cisplatin! was! dissolved! in! PBS! to! a! stock! concentration! of! 1mM.! Paclitaxel! was!made!as!a!1µM!stock!solution!in!PBS!and!PG545,!stored!as!a!20µM!solution!in!PBS,!was!further!diluted!in!media!to!a!1mM!stock!solution.!A2780! and! SKOVL3! cells! in! exponential! growth! were! washed! with! phosphateLbuffered!saline!(PBS),!trypsinized!with!0.25%!trypsin/EDTA!at!37°C,!counted!and!seeded! as! a! single! cell! suspension! in! 200! µl! media! at! a! concentration! of! 5x103!cells/well! in! 96Lwell! plates! and! allowed! to! attach! over! night! at! 37°C.! Serial!dilutions!were!made! from! the! stock! solutions! in! complete! culture!media! and,! to!test!the!drugs!as!single!agents,!cells!were!exposed!to!various!drug!concentrations!between!1L150!µM!for!cisplatin,!1L150!nM!for!paclitaxel!and!1L200!µM!for!PG545!for! 48h.! To! test! drug! combinations,! cells! were! incubated! with! increasing!concentrations!of!cisplatin!(1L25!µM)!or!paclitaxel!(1L75!nM)!without!or!with!the!addition! of! PG545! (2.5! and! 10! µM).! After! a! 48h! incubation! at! 37°C,! 20! µl! MTT!reagent!(5mg/ml)!was!added!to!each!well!and!cells!were!incubated!for!another!2!to!4!hours!at!37°C.!To!terminate!the!experiment,! the!culture!media!was!replaced!with! 100! µl!DMSO.! The! absorbance!was! read! at! 570! nM!with!Victor3!Multilabel!Plate!Reader.!All!proliferation!assays!were!performed!in!triplicate.!!The!sort!of!interaction!between!cisplatin!and!PG545!was!assessed!by!median!effect!analysis,!first!described!by!Chou!and!Talalay!(Chou!and!Talalay!1984).!!The!experiment!was!conducted!similarly! to! the!proliferation!assay,!with!the!only!difference! in! the! drug! treatment.! A2780! cells! were! seeded! as! a! single! cell!suspension!in!200!µl!media!at!a!concentration!of!5x103!cells/well!in!96Lwell!plates!and! were! allowed! to! attach! over! night! at! 37°C.! The! cells! were! then! exposed! to!increasing!concentrations!of!the!chemotherapeutic!for!48h.!DoseLresponse!curves!were! first! determined! for! each! drug! alone! and! the! IC50! value! for! cisplatin! was!calculated! using! the! Calcusyn! Software.! Then! the! doseL! response! curves! were!determined!with!cisplatin!and!PG545!in!combination!at!a!fixed!ratio!equivalent!to!the! ratio! of! their! IC50! values.! Calcusyn! Software! was! used! to! calculate! the!combination! indices! at! the! different! levels! of! cell! kill! (ED).! Combination! index!values!<1!indicate!synergy,!a!value!of!1!indicated!additivity!and!values!>1!indicate!antagonism.!!
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5.2.3 Anoikis*assay*!Anoikis!assay!was!performed!as!previously!described!with!few!modifications!(He,!Ota!et!al.!2010).!A2780!cells!were!plated!in!duplicate!at!a!density!of!4x105!cells/well!in!2ml!growth!media/well!in!6Lwell!ultraLlow!attachment!plates.!PG545!or!cisplatin!was!added!in!a!volume!of!1ml!to!achieve!final!concentrations!of!1L50!µM!for!PG545!and!1L15!µM!for!cisplatin.!Cells!were!treated!in!duplicate!and!incubated!for!48!hours.!After!48!hours,! cells!were! spun!down!at!1500! rpm! for!3!min.!Cells!were! reLsuspended! in!fresh!drugLfree!or!PG545!containing!media!(for!PG545!only!treatment)!and!plated!as! a! single! cell! suspension! at! a! volume! of! 3ml/dish! on! 60mm! dishes.! After! an!incubation!of!8! to!12!hours!at!37°C,!1ml!MTT!reagent!was!added!and!cells!were!incubated!for!another!1!to!4!hours.!After!aspiration!of!the!media,!2ml!DMSO!was!added.!After!transferring!50!µl!of!each!DMSOLcell!dilution!from!the!60!mm!dishes!in!triplicate!to!96Lwell!plates,!already!containing!150!µl!of!fresh!DMSO,!plates!were!read!at!500!nm!with!Victor3!Multilabel!Plate!Reader.!The!same!protocol!was!followed!to!study!the!combination!of!cisplatin!and!PG545.!Cells!were! incubated!with! 2.5! µM! cisplatin!with! and!without! 25! µM! PG545! and!5µM!cisplatin!with!and!without!25!µM!PG545.!To! analyze! the! cleavage! of! PARP,! after! being! plated! as! a! single! cell! suspension!culture,!cells!were!lysed!and!analyzed!by!Western!Blotting!as!described!below.!!!
5.2.4 Xenograft*model*!The!animal!experiments!were!conducted!according!to!an!Institutional!Animal!Care!and!Use!Committee–approved!protocol!and!institutional!guidelines!were!followed.!50! sixLweek! old,! female,! athymic! nude! mice! were! obtained! from! the! National!Cancer!Institute.!Before! injection,! A2780! luciferaseLexpressing! ovarian! cancer! cells! were! washed!with!PBS,!counted!and!resuspended!in!PBS!at!625000!cells/100!µl.!On!Day!0,!1.25!Mio! cells/mouse! were! injected! into! the! intraperitoneal! cavity.! Mice! were!distributed!randomly!into!5!treatment!groups!and!treatment!was!administered!as!
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shown! in! Fig.! 7.! The! first! group! was! a! control! group.! The! second! group! was! a!cisplatin/paclitaxel! combination! treated! group! receiving! 4mg/kg! cisplatin! plus!16mg/kg! paclitaxel! on! Day! 3,! 6,! and! 9! of! the! study.! The! third! group! received! a!combination!of!cisplatin!(4mg/kg),!paclitaxel!(16mg/kg)!and!PG545!(20mg/kg)!on!Day!3,!6,!and!9!followed!by!PG545!treatment!twice!weekly!(20mg/kg).!The!fourth!group!was!treated!with!cisplatin!(4mg/kg)!and!paclitaxel!(16mg/kg)!on!Day!3,!6,!and! 9! followed! by! PG545! treatment! twice! weekly! (20mg/kg).! The! fifth! group!received! PG545! (20mg/kg)! twiceL! weekly.! For! drug! preparation,! cisplatin! was!dissolved!firstly!in!1ml!DMSO!and!then!diluted!in!phosphate!buffered!saline!(PBS)!pH!7.2.!Paclitaxel!and!PG545!were!diluted!in!phosphate!buffered!saline!(PBS)!pH!7.2.!All!drugs!were!administered!i.p.!(intra!peritoneally).!Body!weight!was!measured!twice!weekly!and!tumor!growth!of!5!mice/group!was!measured!radiographically!using!the!IVIS200!system!twice!weekly!until!the!end!of!the!study.!All!mice,!surviving!until!the!end!of!the!study,!were!sacrificed!on!day!63.!To! examine! the! antitumor! efficacy! of! each! treatment! regimen,! all! mice! were!autopsied!at!death.!!
5.2.5 Western*blot*analysis*!Generation!of!cell!lysates!Western!plot!analysis!was!performed!using!protein! lysates!of! snapLfrozen! tumor!samples! of! three! mice/! treatmentLgroup.! SnapLfrozen! tumor! samples! were!homogenized! and! lysed! in! a! cold! lysis! buffer! containing! a! proteaseLinhibitor!cocktail!(Roche,!Indianapolis,!IN)!for!30!minutes!on!ice,!centrifuged!at!13,000!rpm!for!30!minutes!and!supernatant!was!collected.!!Lysis!buffer!AM1!(active!motif):!20!mM! Hepes!0.1!mM! EDTA!400!mM! Sodium!Chloride!10!mM!! Sodium!Fluoride!10!µM! Sodium!Molybdate!
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1!mM!! Sodium!Metavanadate!10!mM! PNPP!10!mM!! BetaL!glycerophosphate!20%! glycerol!Solution!pH!7.5! !!Freshly!added:!Protease!inhibitor!cocktail!!Determination!of!protein!concentration!Protein! concentration!was! estimated!by! the!Bradford!method! (BioRad,!Hercules,!CA).! The! Bradford! protein! assay,! a! colorimetric! protein! assay,! is! based! on! the!absorbance! shift! of! Coomassie! Brilliant! Blue! GL250! dye! in! response! to! various!concentrations! of! protein.! The! Bradford! reagent! (5x)! was! diluted! in! a! 1:5! ratio!with!deionized!water.!To!estimate!protein! concentrations,!1000!µl!of! the!diluted!Bradford!reagent!was!mixed!with!1000!µl!ddH2O!and!1µl!of!protein!sample!and!optical!density!of!the!reaction!was!measured!at!595!nm!with!a!spectrophotometer.!!SDSL!polyacrylamide!gel!electrophoresis!For! sample! preparation,! protein! samples! with! equal! amounts! of! protein! were!resolved! by! SDSLPAGE! (polyacrylamide! gel! electrophoresis)! gel! and!electrotransferred! onto! PVDF! (EMD! Millipore,! Billerica,! MD)! or! nitrocellulose!(BioRad,!Hercules,!CA)!membranes.!For! separation! of! proteins,! SDSL! PAGE! was! used! and! gels! and! solutions! were!freshly!prepared.!Gels! from!7.5%! L15%!were!prepared,!depending!on! the! size!of!the! proteins! to! be! separated! and! after! polymerization!were! overlaid!with! a! 4%!stacking!gel.!Protein!samples!with!equal!amounts!of!protein!were!denatured!by!the!addition! of! 4x! nupage! LDS! sample! buffer! and! heated! for! 3! minutes! at! 90! °C.!Samples!were!then!applied!to!the!slots!of!a!4%!stacking!gel.!The!cell!was!filled!up!with!running!buffer!and!samples!were!run!for!approximately!three!hours!at!60!V.!!!!!
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Resolving!gel:!! 7,5%! 10%! 12%! 15%!30%!Gel! 5!ml! 6.7!ml! 6!ml! 10!ml!ddH20! 9.8!ml! 8.0!ml! 6.8!ml! 4.8!ml!4x! resolving!buffer! 5!ml! 5!ml! 5!ml! 5!ml!10%!APS! 200!µl! 200!µl! 200!µl! 150!µl!TEMED! 20!µl! 20!µl! 20!µl! 20!µl!!Stacking!gel:!! 4%!!30%!Gel! 1.3!ml!ddH2O! 6.1!ml!Stacking!buffer! 2.5!ml!10%!APS! 100!µl!TEMED! 10!µl!!Sample!buffer:!10%! Glycerol!141!mM! Tris!base!106!mM! HCl!2%! LDS!0.51!mM! EDTA!0.22!mM! SERVA!Blue!G250!0.175!mM! Phenol!red!pH!8.5! !!!!!!!
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TrisLglycineLSDS!running!buffer!(1x):!25!mM! Tris!HCl!192!mM! Glycine!0.1%! SDS!pH!8.3! !!Western!blotting!To!transfer!the!proteins!on!a!membrane,!carbon!paper!and!nicrocellulose!or!PVDF!membrane! were! cut! to! the! size! of! the! separating! gel! and! the! stacking! gel! was!removed.!The!membrane!was!activated!by!dipping!it!for!one!minute!into!methanol,!and!the!transfer!sandwich!was!set!up!in!the!gel!holder!cassette!from!bottom!to!top!as!followed:!foam,!carbon!paper,!gel,!membrane,!carbon!paper,!foam.!The!transfer!was! done! with! a! voltage! of! 60V! for! 1! hour! and! 20! minutes.! After! the! protein!transfer,!the!membrane!was!blocked!for!one!hour!in!blocking!solution!(5%!non!fat!milk! dissolved! in! TBST)! and! immunoblotted!with! the! primary! antibody! (1:500)!overnight!at!4°C.!Post!incubation,!the!membrane!was!washed!in!TBST!and!probed!with! a! HRPLconjugated! secondary! antibody! (1:3000)! in! blocking! buffer! for! 90!minutes!at!RT.!After!another!washing!step,!the!proteins!of!interest!were!visualized!by!enhanced!chemiluminescence!(ECL)!(Amersham,!Buckinghamshire,!UK).!!Transfer!buffer:!premixed!!Washing!buffer!(TBST):!20!mM! Tris!base!140!mM! NaCl!0.05%! Tween!20!pH!7.6! !!!!
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6.1.1! PG545* decreases* cell* viability* of* A2780* and* SKOV3* cells* in* a* dose*
dependent*manner*!
!!





Fig.!3:!Percent!(%)!cellular!viability!of!ovarian!cancer!cell!lines,!A2780!and!SKOV3!treated!with!cisplatin!or!paclitaxel!+/L!PG545.!A.!Viability!(%)!of!A2780!and!SKOV3!cells!treated!with!cisplatin!alone,!cisplatin!+!2.5!µM!PG545,!or!cisplatin!+!10!µM!PG545.!B.!Viability!(%)!of!A2780!and!SKOV3!cells!treated!with!paclitaxel!alone,!paclitaxel!+!2.5!µM!PG545,!or!paclitaxel!+!10µM!PG545.!!!As!platinum!compounds!and!taxanes!are!the!key!components!of!chemotherapy!for!ovarian!cancer!patients,!we!next!examined!whether!PG545!can!enhance!cisplatin!and!paclitaxel!induced!cytotoxicity!in!A2780!and!SKOV3!ovarian!cancer!cells.!Cells!were!exposed! to! increasing!concentrations!of!cisplatin!or!paclitaxel!with!or!without!the!addition!of!PG545!(2.5!µM!and!10!µM)!and!cell!viability!was!assessed!by!MTT!assay!after!48h.!To!describe!the!additive!effect!of!PG545!on!cisplatin!and!paclitaxel! efficacy,! we! analyzed! if! the! addition! of! PG545! can! reduce! the! dose! of!these!antiLcancer!drugs!needed!to!achieve!50%!of!growth!inhibition!(IC50).!!Both!cell! lines,!A2780!and!SKOV3!were!inhibited!in!proliferation!by!cisplatin!and!paclitaxel.! In! A2780! cells! the! IC50! for! cisplatin!was! 6.1µM.! In! combination!with!PG545,!less!than!halve!the!dose!of!cisplatin,!2.4!µM,!was!sufficient!to!achieve!50%!growth!inhibition.!A!greater!additional!cytotoxic!effect!of!the!higher!dose!of!PG545!
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(10µM)! compared! to! the! lower! dose! (2.5µM)! was! only! seen! when! the! dose! of!cisplatin! exceeded! 5µM.! When! SKOV3! cells! were! treated! with! increasing!concentrations! of! cisplatin,! a! cisplatin! concentration! of! 4.4! µM!was! sufficient! to!achieve!the!IC50!when!treated!with!both,!10!µM!PG545!and!cisplatin,!instead!of!6.4!µM!when!treated!only!with!cisplatin.!The!higher!dose!of!PG545!had!more!cytotoxic!effect! in! comparison! to! the! lower! dose! when! cisplatin! was! above! 5µM.! When!A2780!cells!were!treated!with!paclitaxel,!the!addition!of!10!µM!PG545!reduced!the!IC50L!paclitaxel!dose!from!9.1!nM!to!5.5!nM.!Addition!of!PG545!to!increasing!doses!of!paclitaxel!demonstrated!an!additional!effect!in!paclitaxel!doses!above!5!nM!with!the! higher! PG545! dose! of! 10µM,! while! the! lower! dose! enhanced! the! effect! of!paclitaxel!only!in!doses!above!10!nM.!In!SKOV3!cells,!concentrations!up!to!50!nM!of!paclitaxel!were!not!sufficient! to!achieve!an! IC50,!but! the!adding!of!10!µM!PG545!led!to!an!IC50!of!44.6!nM!for!paclitaxel.!Both!PG545!concentrations!had!a!similar!additional!cytotoxic!effect.!!!!To!further!analyze!the!nature!of!the!combination!of!PG545!and!cisplatin,!we!used!the!combination!index!method!as!described!by!Chou!and!Talalay!(Chou!and!Talalay!1984).!Serial!dilutions!were!prepared,!based!on!the!IC50!of!each!drug!providing!a!1:1!equipotent!cisplatin:!PG545!ratio!to!ensure!that! the!contributing!effects! from!each!drug!were!equal.!To!determine!the!nature!of!the!interaction!between!PG545!and!cisplatin,!we!used!median!effect!analysis,!which!offers!a!way! to!examine! the!degree! of! synergism! and! antagonism! at! different! levels! of! cell! kill.! This! analysis!provides!a!combination!index!(CI),!where!a!CI!<1!indicates!synergism!and!a!CI>1!indicates! antagonism! (Chou! 2006).! The! smaller! the! value! <1,! the! greater! is! the!degree! of! synergy! and! the! greater! the! value! >1,! the! greater! is! the! antagonistic!effect.!!A!synergistic!effect!of!cisplatin!and!PG545!was!observed,!when!the!effective!dose!(ED)!of!the!drug!combination!inhibited!cell!viability!by!50%!with!a!CI!of!0.93.!At!a!low! level!of! cytotoxicity! (ED20)!no!synergistic!effect!was!seen.!Synergy!occurred!when!the!level!of!cell!kill!exceeded!45%!(ED45).!A!significant!synergistic!effect!was!seen!only!between!ED70!and!ED85.!At!the!90%!level!of!cell!kill,!the!combination!of!cisplatin! and! PG545! had! a! CI! of! 0.73,! indicating! synergy! at! levels! of! high!cytotoxicity.!
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6.1.3 PG545*decreases* cell* survival*and*potentiates* the* effect* of* cisplatin* in*
suspension*culture*A.! ! ! ! ! ! B.!
!C.!
!!!
Fig.!4:!Anoikis!assay!under!PG545!treatment.!A.!Percent!(%)!cell!viability!under!PG545!treatment!in!adhesion!culture.!B.!Percent!(%)!cell!viability!under!PG545!treatment!in!suspension!culture.!C.!Increased!PARPLcleavage!under!PG545!treatment!in!suspension!culture.!!!In! this! experiment,! we! examined! the! effect! of! PG545,! cisplatin,! and! the!combination!of!both!drugs!on!cancer!cells! that!have! lost!anchorageL!dependence.!Suspension!culture!was!used!to!simulate!extracellular!matrix!detachment!growth. Recent! studies! indicated! that!malignant! cells! are! able! to! survive! the!detachment!from!a!primary! tumor!and! thus!acquire!metastatic!potential! only! after! acquiring!new! features.! ! One! feature! is! overcoming! anoikis,! a! type! of! apoptotic! cell! death,!which! is! triggered! by! detachment! of! cells! from! the! extracellular! matrix!(ECM)(Kandala! and! Srivastava! 2012).! In! other! words,! cells! surviving! in!detachment!growth!conditions!have!lost!sensitivity!to!anoikis!signals!and!become!anoikis! resistant.! To! determine! if! PG545! and! cisplatin! are! able! to! reduce! the!number!of!cells!surviving!under!detachment!growth!condition!and!affect! floating!tumor! cells,! A2780! cells! were! cultured! as! a! suspension! culture! on! ultraLlow!
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Fig.!5:!Anoikis!assay!under!cisplatin!and!combination!treatment.!A.!Percent!(%)!cell!viability!under!cisplatin!treatment!in!suspension!culture.!B.!Percent!(%)!cell!viability!under!combination!treatment!in!suspension!culture.!!For! better! evaluation! and! comparison,! the! same! experiment!was! also! conducted!with!cisplatin,!the!standard!firstLline!agent!in!the!treatment!for!ovarian!cancer.!The!results! in!Fig.!5A!show!that!cisplatin!potently!decreases!cell!viability!and!2.5!µM!cisplatin! were! sufficient! to! reduce! the! cell! survival! to! under! 50%.! At! 10! µM,!cisplatin!decreased!viability!to!23.8%!and!PG545!to!51.3%,!and!at!a!concentration!of! 15! µM! cisplatin! only! 15%! of! cells! survived! the! treatment.! Fig.! 5B! shows! the!effect!of! the! combination!of! cisplatin!and!PG545.!For! this! experiment,! cells!were!
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treated!with!2.5!µM!or!5!µM!cisplatin!with!and!without!25!µM!PG545!for!48h.!The!HSLmimetic!was! able! to! enhance! the! cytotoxic! effect! of! cisplatin! and! to!decrease!survival!at!2.5!µM!cisplatin!by!an!additional!9.8%!and!at!5!µM!cisplatin!by!7.7%.!!
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6.2.1 PG545* as* a* combination* and* maintenance* drug* prolongs* overall*
survival*in*an*in*vivo*ovarian*cancer*model*!
!




Fig.!8:!KaplanL!Meyer!survival!analysis.!!Untreated!mice!had!a!mean!survival!3.5!weeks.!Two!mice!survived!until!the!end!of!the!study!and!were!tumorLfree.!Mice!treated!with!cisplatin!and!paclitaxel!showed!a!mean!survival!of!6.5!weeks.!Mice,!which!received!PG545!as!a! single!agent,!had!a!mean!survival!of!about!6!weeks.!The!study!thus!showed!that!PG545,!administered!twice! weekly! as! a! single! agent! and! treatment! with! 3! cycles! of! standard!chemotherapeutics! were! able! to! significantly! (! p<0.05! and! p<0.01,! respectively)!prolong!survival!compared!to!the!control!group.!!PG545,! given! as! a! maintenance! drug! after! cisplatin! and! paclitaxel! frontLline!therapy,!prolonged!the!mean!survival!to!nearly!8!weeks.!!The! most! powerful! antiLcancer! regime! was! the! combination! of! PG545,! cisplatin!and!paclitaxel! for! three!cycles! followed!by!a!PG545!maintenance! therapy.! In! this!group,!the!median!survival!was!not!reached!as!90%!of!mice!survived!nine!weeks!until! the! end! of! the! study.! The! addition! of! PG545! to! standard! chemotherapy!followed! by! PG545! maintenance! treatment! showed! a! significant! (p<0.05)!prolongation! of! survival! compared! to! mice! treated! only! with! the! traditional!
















chemotherapeutics!cisplatin!and!paclitaxel.!These!results!show!that!the!addition!of!PG545! to! standard! chemotherapy! followed! by!maintenance! therapy!with! PG545!produces!a!significant!overallLsurvival!benefit!in!ovarian!cancerLbearing!mice.!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Fig.!10:!One!autopsied!mouse/!group!and!the!excised!tumor.!!To!further!examine!the!efficacy!of!each!treatment!regime,!all!mice!were!autopsied!at! death! and! the! tumor! was! excised.! Fig.! 10! shows! one! representative!mouse/group!and!the!excised!tumor.!The!amount!of!mice!bearing!tumor!and!the!mean!tumor!weight!at!autopsy!are!indicated!in!Table!1.!!!
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Fig.!11:!Body!weight!development!of!tumor!bearing!mice!during!the!course!of!the!study!!As!previous! studies! indicated!weight! loss! in! tumor!bearing!mice!associated!with!PG545! treatment,! all!mice!were!weighed! twice!weekly! during! the! course! of! the!study! (Fig.! 11).! Additionally,! abdominal! circumference! was! measured! during!autopsy!(Table!1).!We!observed!that!all!mice!treated!with!PG545!showed!an!initial!weight! loss.! Despite! this! initial! weight! loss,! mice! did! not! keep! on! losing!weight!during!the!course!of!the!study.!One!mouse!receiving!PG545!as!a!single!agent!had!to!be!sacrificed!due! to! low!weight.!The! lower!weight! in! the! three! treatment!groups!receiving! PG545! treatment! compared! to! the! control! and! cisplatin! and! paclitaxel!treated!mice!corresponds!to!the!lower!mean!tumor!weight!by!the!time!of!autopsy!and!the!lower!abdominal!circumference.!!!!!!!!!!!!!
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6.2.3 PG545* has* effect* on* tumor* necrosis* and* on* angiogenesis* in* ovarian*
























Fig.! 14:! Stem! cell! marker! expression! in! tumor! samples! of! untreated! mice,! cisplatin+!paclitaxel! treated! mice,! PG545! treated! mice! and! cisplatin+! paclitaxel+! PG545! day! 10!treated!mice.!!Since! we! showed! that! the! addition! of! PG545! to! the! regular! chemotherapeutic!regimen! inhibits! regrowth! of! ovarian! cancer! cells! after! response! to! firstLline!chemotherapy,! resulting! in! a! lower! rate! of! relapse! in#vivo,!we! next! analyzed! the!expression!of! cancer! stem!cell!markers! in!our! tumor! samples.!The!expression!of!cancer!stem!cell!specific!markers!indicates!the!existence!of!tumor!cells!with!stem!cellLlike!properties.!This!group!of!cells!survives!chemotherapy!and!is!responsible!for!chemoLresistance!and!relapse!after! initial!remission!(Binaschi,!Simonelli!et!al.!2011).! The! aim! was! to! determine! if! PG545! has! the! potency! to! affect! this! cell!population.!We!therefore!determined!the!expression!of!characteristic!cancer!stem!cell! markers! (Nanog,! bmiL1! and! octL4)! in! samples! of! the! excised! tumors! using!western!blot!analysis.!The!expression!of!both,!OctL4!and!nanog!is!essential!for!the!maintenance! of! embryonic! stem! cell! properties! (Samardzija,! Quinn! et! al.! 2012).!“BmiL1,! a! member! of! the! polycomb! group! (PcG)! family,! participates! in! the! selfLrenewal! and! maintenance! of! CSCs”! (Tomao,! Papa! et! al.! 2013).! Moreover,! it! can!enable!cells!to!escape!apoptosis!(Zhan,!Wang!et!al.!2013).!OctL4!is!a!member!of!the!POU!family!of!transcription!factors!and!plays!a!crucial!role!in!maintenance!of!selfLrenewal! and! pluripotency! in! embryonic! stem! cells.! Nanog! is! another! key!
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transcription! factor! essential! for! maintaining! stem! cell! properties! such! as! selfLrenewal!and!pluripotency!(Siu,!Wong!et!al.!2013).!The! expression! of! the! cancer! stem! cell! markers! bmiL1,! nanog! and! octL4! was!determined!in!three!tumor!samples!per!treatment!group.!Due!to!the!lack!of!tumor!material!of! the! cisplatin,!paclitaxel! and!PG545!day!3! treated!group,!we!were!not!able!to!include!this!group!in!the!analysis.!Compared! to!mice! receiving!any!kind!of! chemotherapy,! the! three! samples!of! the!control!group!showed!the!lowest!expression!levels!of!all!three!stem!cell!markers.!Especially!cisplatin!and!paclitaxel!treated!mice!showed!enhanced!expression!of!all!three! stem!cell!markers,! compared! to! the!control.!This! finding! is! consistent!with!other!publications!that!report!an!enhanced!expression!of!cancer!stem!cell!markers!(including!nanog!and!octL4)!in!chemotherapy!surviving!ovarian!cancer!cells!in#vitro#(Abubaker,!Latifi!et!al.!2013).!!For!bmiL1!and!octL4!the!highest!expression!levels!were!found!in!tumors!from!mice,!treated!only!with!the!standard!primary!chemotherapy.!Tumors!from!mice!treated!with!PG545!alone!or!PG545!as!a!maintenance!agent!after!firstLline!therapy!tended!to!express!lower!levels!of!bmiL1!and!octL4!compared!to!the!cisplatin!and!paclitaxel!treated!group,!but!slightly!higher!levels!compared!to!the!control.!While!no!distinct!difference!was!seen!in!the!expression!levels!of!bmiL1!in!the!PG545!treated!group!compared!to! the!group,!receiving!PG545!as!a!maintenance!agent,! two!samples!of!the!maintenance!group!showed!higher!levels!of!octL4!expression!compared!to!the!PG545! treated! group.! All! three! cisplatin+! paclitaxel! group! samples! showed! high!expression! levels! for! nanog.! PG545! treated! samples! showed! similar! expression!levels!in!two!tumors!and!with!addition!of!PG545!as!a!maintenance!drug,!only!one!tumor!showed!a!high!nanog!expression!level.!!!!!!!!!
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7 Discussion!!Epithelial! ovarian! cancer! is! the! leading! cause! of! death! from! gynecologic!malignancies!and!is!referred!to!as!the!‘silent!killer’!(Binaschi,!Simonelli!et!al.!2011).!The! lethality! of! ovarian! cancer!mainly! originates! from! the! inability! to! detect! the!disease!at!an!early,!organL!confined!stage!when!the!disease!is!most!treatable,!and!the!lack!of!effective!therapies!to!cure!advancedL!stage!disease!(Naora!and!Montell!2005).!Since!early!symptoms!are!unspecific!and!vague,!“seventy!percent!of!women!present!with! advanced! disease! in!which! the! tumor! has! spread! to! the! peritoneal!surfaces! of! the! upper! abdomen”! (Cannistra! 1993).! The! standard! treatment,!aggressive! debulking! surgery! followed! by! six! cycles! of! platinumLbased!chemotherapy,! results! in! complete! clinical! remission! in! up! to! 75%! of! patients.!However,! 75%! of! the! responders!will! relapse!within! a!median! time! of! 18! to! 28!months! (Mei,! Chen! et! al.! 2013).! Currently,! there! are! no! chemotherapeutics! that!effectively!prevent!and! inhibit! the!recurrence!of!ovarian!cancer.!Thus,!efforts!are!still! ongoing! to! identify! new! antiLcancer! agents!with! the!main! focus! on! targeted!therapy.!One!of!these!newly!identified!agents!is!PG545,!a!heparanLsulfate!mimetic!which! uses! a! dual! approach! as! an! antiL! cancer! therapeutic,! with! both,! antiL!angiogenic!and!antiL!metastatic!potential.!Due!to!its!mechanism!of!action,!PG545!is!a! promising! agent! to! target! some!main! features! of! ovarian! cancer.! Typical! traits!that! present! a! target! for! PG545! are! the! characteristic! overexpression! of! VEGF,! a!growth! factor! promoting! angiogenesis! (Binaschi,! Simonelli! et! al.! 2011)! and! the!highly!metastatic!potential!of!this!disease.!As!the!mechanism!of!action!of!PG545!make!this!drug!a!promising!agent!to!target!some!main!features!of!ovarian!cancer,!the!combination!of!PG545!and!current!firstLline! therapy! as! a! triple! drug! regimen! might! enhance! the! efficacy! of! initial!chemotherapy!resulting! in!a!decrease!or!eradication!of!minimal! residual!disease.!Additionally,! as! the!mechanism! of! action! of! PG545! differs! from! that! of! standard!chemotherapeutics! cisplatin! and! paclitaxel! it! might! even! affect! chemoLresistant!disease! and! as! it! is! able! to! interfere! with! fundamental! steps! in! tumor! cell! reLgrowth,! inhibit! the! growth! of! recurrent! chemoLresistant! cancer.! Hence,! in! this!study! we! sought! to! test! the! addition! of! PG545! to! standard! chemotherapy! and!
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identified! the!most!potent! treatment! regimen.!Furthermore,!we! investigated! in!a!maintenance!setting,! if!one!of!the!regimens!is!effective!in!maintaining!the!clinical!complete! response! after! initial! chemotherapy! resulting! in! progressionL! free! and!overall!survival!benefit.!!First,! in#vitro!analysis!of!PG545!was!performed!to!assess!the!effect!of!PG545!as!a!single! agent! on! A2780! and! SKOV3! ovarian! cancer! cells.! PG545! was! found! to!decrease! the! viability! of! ovarian! cancer! cells! in! a! doseLdependent! manner.! The!concentration!necessary!to!inhibit!cell!growth!by!50%!(IC50)!was!90!µM!in!A2780!and!100!µM!in!SKOV3!cells.!Currently,! the!most! active! agent! in! the! treatment! of! ovarian! cancer! is! cisplatin,!which!often!produces!good! initial! therapeutic! responses! (Jekunen,!Christen!et!al.!1994).! Unfortunately,! resistance! to! cisplatin! develops! regularly! and! leads! to!chemotherapeutic!failure!(Jekunen,!Christen!et!al.!1994).!As!it!is!nonetheless!a!very!important! agent! in! the! treatment! of! ovarian! cancer,! there! is! a! strong! interest! in!identifying! agents! that! synergistically! enhance! cisplatin! activity.! To! determine! if!PG545!has!this!ability,!we!tested!this!drug!in!combination!with!the!commonly!used!chemotherapeutic! agents! cisplatin! and! paclitaxel.! When! tested! in! combination!PG545! potentiated! cisplatinL! and! paclitaxelL! induced! cytotoxicity! in! A2780! and!SKOV3! in# vitro! and,! in! combination! with! PG545,! lower! concentrations! of! these!traditional! chemotherapeutics! were! sufficient! to! obtain! the! same! antiL! cancer!effect.!This!in#vitro!finding!supports!the!hypothesis!that!the!combination!of!PG545!and! current! frontLline! chemotherapy! to! a! threeLdrug! regimen! could! enhance! the!efficacy! of! initial! chemotherapy.! Moreover! this! data! is! consistent! with! in# vivo#results,! which! showed! that! combination! of! PG545! and! cisplatin! or! paclitaxel!increased! the! antiLtumor! effect! in! ovarian! cancer! bearing! mice,! compared! to!cisplatin!or!paclitaxel!single!agent!therapy.!From! a! clinical! perspective,! a! reduction! of! the! cisplatin! and! paclitaxel! dose! is! of!great!interest,!as!it!may!lead!to!a!reduction!of!toxic!side!effects!and!allow!patients!to!perform!more!treatment!cycles!with!an!enhanced!quality!of!life.!!As!well!as!an! inhibitory!effect!on!primary! tumor!growth,!PG545!has!shown!antiL!metastatic! potential! in! various! in# vitro# and! in# vivo! experiments.! Metastasis! in!
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ovarian!cancer!is!a!multiLstage!process!including!(a)!disconnection!of!intercellular!adhesions!and!detachment!of!single!cells! from!the!primary!tumor!(b)!single!cells!surviving!the!circulation!in!the!peritoneal!fluid!(c)!attachment!to!distant!sites!and!(d)!growth!at!metastatic!sites!(Lengyel!2010,!Arvatz,!Shafat!et!al.!2011).!PG545!has!shown! to! inhibit! several! of! these! steps.! In! initial! studies,! the! heparanL! sulfate!mimetic!was!shown!to!potentially!inhibit!the!enzyme!heparanase!(Ki=!6nM)(Dredge,!Hammond! et! al.! 2010),! which! is! critical! for! the! remodeling! and! loosening! of!extracellular!matrix!and!whose!activity! is! strongly! involved! in! cell!dissemination!associated!with!tumor!metastasis!(a).!!Recently,!our! laboratory!has! shown,! that!PG545!reduces! the!adhesion!of!ovarian!cancer! cells! to! mesothelial! cells! in# vitro! (data! not! published).! In# vivo,# the!mesothelium! covers! the! abdominal! cavity! and! inner! organs! and! is! thus! the! first!surface!encountered!by!tumor!cells!circulating!in!the!peritoneal!fluid.!Inhibition!of!adhesion! to! these! cells! leads! to!a!decreased!attachment!of! tumor! cells! to!distant!sites,! hence! the! inhibition! of! step! (c).! ! As! angiogenesis! is! necessary! for! tumor!growth!at!the!metastatic!site,!PG545!may!also!influence!step!(d).!In! this! study! we! tested! if! PG545! has! an! effect! on! cancer! cells! that! have! lost!anchorageLdependence.!In#vivo,!tumor!cells!are!in!anchorageL!independent!growth!condition!between!step!(a)!and!(c),!when!they!circulate!as!detached!cancer!cells!in!the! peritoneal! fluid! (b).! Following! the! detachment! from! the! ECM,! cells! usually!undergo! an! intrinsically! programmed! cell! death! (apoptosis)! called! anoikis!(Kandala! and! Srivastava! 2012).! Thus,! in! order! to! survive! under! detachment!growth! conditions! and! to!metastasize,! a! cancer! cell! has! to! acquire! new! features.!One!primary! feature! of!metastasizing! tumor! cells! is! the! loss! of! sensitivity! to! the!anoikis! signal,! allowing! them! to! survive! under! suspension! conditions! and! to!circulate!in!the!peritoneal!fluid!(He,!Ota!et!al.!2010).!As!ovarian!cancer!commonly!metastasizes! through! the! peritoneal! fluid,! studying! cells! in! detachmentLgrowth!condition!it!is!of!great!interest!in!this!type!of!cancer.!It!was,!for!example,!recently!shown!that!treatment!with!diindolylmethane!reduced!anoikis!resistance!in!various!ovarian!cancer!cell!lines!(Kandala!and!Srivastava!2012).!In!this!study,!we!showed!that!PG545!and!cisplatin!were!able!to!decrease!survival!rates! of! cells! cultured! in! anchorageLindependent! growth! condition! in! a!concentrationLdependent! manner.! The! decrease! of! cell! viability! was! associated!
Discussion!_______________________________________________________________________________________________!
!53!
with! an! increase! in! the! cleavage! of! the! apoptosis! marker! PARP,! indicating! an!increased!number!of!suspended!cells!undergoing!apoptosis.!These!results!suggest!that! PG545! induces! apoptosis! in! suspension! culture,! possibly! by! overcoming!anoikis! resistance,! resulting! in! an! increase!of! apoptotic! cell!death!and!decreased!cell! survival! rates! under! PG545! treatment.! Thus,! PG545!might! effectively! inhibit!step! (b)! of! the!metastasis! process,! the! circulation!of! detached! tumor! cells! in! the!peritoneal!fluid.!Furthermore,!PG545!was!able!to!potentiate!the!effect!of!cisplatin!on! A2780! ovarian! cancer! cells! in! suspension! culture.! It! was! also! observed! that!PG545! treatment! prevents! the! formation! of! cellLcell! mediated! multicellular!aggregates! in! a! concentrationLdependent! manner.! Previous! studies! report! that!cellLcell!adhesion!mediated!multicellular!aggregate!formation!leads!to!activation!of!Erk,! PI3K/Akt! and! other! survival! pathways! and! that! this! stimulation! of!intracellular! survival! signaling! can! sustain! the! evasion! of! anoikis! in! suspension!culture!(Zhong!and!Rescorla!2012).!!Knowing! that! PG545! directly! inhibits! growth! factor! mediated! signaling! through!blockage! of! heparinLbinding! growth! factors! (Winterhoff,! Freyer! et! al.! 2015)! and!that! PG545! impedes! cellLcell!mediated!multicellular! aggregate! formation;! PG545!has! two!effects,! that!both! lead! to!a!decrease!of!growth! factor!mediated!signaling!and! therefore! deprive! the! cell! of! this! mechanism! to! evade! anoikis.! Thus,! it! is!possible! that! anoikisLresistant! cells! become! anoikisLsensitive! under! PG545!treatment.!The!underlying!principle!of!how!PG545!inhibits!cellLcell!adhesion!and!if!it!affects!anoikis!resistance!have!yet!to!be!elucidated!and!require!further!research.!The!antiL!metastatic!properties!of!PG545!are!not!only!important!for!metastasis!but!also!with!regard!to!disease!recurrence!after! firstL! line!chemotherapy,!and!thus!of!great! interest!for!this!study.!Disease!recurrence!originates!from!minimal!residual!disease,!either!at!the!location!of!the!primary!tumor!or!on!metastatic!sites.!!As!PG545!is!able!to!decrease!the!survival!of!floating!tumor!cells!in#vitro,!it!might!be!able! to! decrease! the! spread! of! cancer! cells! from!minimal! residual! disease! after!cytoreduction!and!consequently!the!risk!of!recurrence!on!metastatic!sites.!As!it!has!shown!to!enhance!the!efficacy!of!cisplatin!and!paclitaxel!induced!cytotoxicity,!the!three! drug! combination! might! be! able! target! minimal! residual! disease! more!effectively.!!
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There!is!currently!a!strong!rational!to!target!angiogenesis!as!an!approach!for!novel!antiL!cancer!strategies!and!in!the!search!for!maintenance!agents!that!may!impede!disease! recurrence! (Mabuchi,! Terai! et! al.! 2008).! ! Since! it! has! been! shown! that!tumors! require! vascular! blood! supply! to! grow! beyond! 1! to! 2! mm! in! diameter!(Folkman!1990),!minimal! residual!disease! remaining!after! cytoreductive! surgery!and! complete! clinical! response! to! firstLline! chemotherapy! should! depend! on!angiogenesis! for! proliferation,! invasion! and! metastasis! (Mabuchi,! Terai! et! al.!2008).! Similar! to! our! study,! a! Japanese! study! group! reported! in! 2008! a! survival!benefit! in! mice! treated! with! the! angiogenesis! inhibitor! bevacizumab! in! a!maintenance! setting! (Mabuchi,! Terai! et! al.! 2008).! Used! in!maintenance! therapy,!bevacizumab!significantly!inhibited!the!regrowth!of!ovarian!cancer!and!50L60%!of!mice!treated!with!cisplatin!and!bevacizumab,! followed!by!a!maintenance!therapy!with! bevacizumab,! survived! until! the! end! of! the! study! without! evidence! of!recurrence!(Mabuchi,!Terai!et!al.!2008).!Several!clinical!trials!have!studied!the!efficacy!of!adding!bevacizumab!to!standard!chemotherapy,! both! in! firstLline! treatment! (! ICON7! and! GOL0218! trial)! ! and! in!patients!with!recurrent!ovarian!cancer!(!OCEANS!and!AURELIA!trial)!(Aravantinos!and!Pectasides!2014).!It!was!shown!that!the!addition!of!bevacizumab!to!standard!chemotherapy! in! firstLline! treatment! improved! progressionLfree! survival! in!ovarian!cancer!patients,!with!a!greater!benefit!in!terms!of!progressionL!free,!as!well!as!overall!survival!in!women!with!a!high!risk!of!disease!progression!(Perren,!Swart!et!al.!2011).!The!use!of!bevacizumab!has!also!shown!significant!efficacy!benefits!in!patients!with!recurrent!ovarian!cancer!(Aravantinos!and!Pectasides!2014).!!As! recent! studies! have! shown! that! antiLangiogenic! approaches! can! promote!metastasis! in! animal!models! of! cancer! (Ostapoff,! Awasthi! et! al.! 2013)! and! drug!resistance! was! reported,! the! strategy! of! targeting! angiogenesis! has! been!questioned! (Ostapoff,! Awasthi! et! al.! 2013)! and! future! research! is! focusing! on!agents!that!inhibit!metastasis!as!well!as!angiogenesis.!!!One! aim! of! our! study! was! to! analyze! the! efficacy! of! a! combination! therapy! to!prevent!or!inhibit!relapse!of!ovarian!cancer!in!a!maintenance!setting.!We!therefore!developed! an! in#vivo! recurrence!mouse!model! in!which!mice,! treated!with! three!cycles!of!cisplatin!and!paclitaxel!firstLline!chemotherapy,!showed!regrowth!of!the!
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disease!after! initial! treatment!response,!visualized!by!IVIS! luminescence!imaging.!We!used!this!model!to!identify!the!most!effective!treatment!schedule!and!test!if!a!combination!therapy!followed!by!a!maintenance!therapy!with!PG545!is!effective!in!eradicating!or!reducing!the!minimal!residual!disease!burden.!!To! our! knowledge,! this! is! the! first! study! showing! that! treatment! with! PG545,!administered! as! a! single! agent,! not! only! inhibits! and! decelerates! primary! tumor!growth,! but! leads! to! prolonged! overall! survival! in! ovarian! cancer! bearing! mice!compared! to!an!untreated! control! group! (p<0.05).!The! significantly! lower! tumor!weight!at!time!of!death,!the!inhibitory!effect!on!tumor!growth,!seen!in!the!imaging,!and!the!survival!benefit,!emphasizes!the!antiLcancer!efficacy!of!PG545!as!a!single!agent! in# vivo.! Three! cycles! of! chemotherapy! with! cisplatin! and! paclitaxel! also!significantly! prolonged! the! overall! survival! of! mice! (p<0.01).! Although! this!treatment! regime! led! to! full! remission! in! some! mice,! it! was! not! sufficient! to!prevent!disease!recurrence.!The!addition!of!PG545!as!a!maintenance!agent,!following!initial!chemotherapy,!led!to!further!survival!benefit.!Mice!did!not!show!relapse!after!initial!remission!in!the!imaging!and!a!reduced!number!of!mice!were!tumorLpositive!at!the!time!of!autopsy,!compared! to! the! cisplatin! and! paclitaxelL! treated! group.! The! direct! addition! of!PG545! to! standard! chemotherapy! showed! a! significant! (p<0.05)! survival! benefit!compared!to!conventional!treatment.!This!antiLcancer!regimen!was!able!to!sustain!disease!remission!and!impede!recurrence!of!the!disease!and!only!one!mouse!was!tumorLpositive! at! time! of! death.! The! fact! that! the! direct! addition! of! PG545! to!standard!chemotherapy!is!more!potent!than!the!maintenance!regimen!mirrors!our!
in#vitro!data,!where!PG545!has!shown!to!potentiate!the!cytotoxic!effect!of!cisplatin!and! paclitaxel! and! suggests! that! addition! of! PG545! to! firstLline! chemotherapy!might! make! it! more! effective.! The! enhanced! response! to! initial! treatment! may!reduce!minimal!residual!disease!and!thus!decrease!the!risk!of!recurrence.!!Targeting! angiogenesis! is! based! on! the! knowledge! that! growth! of! new! blood!vessels! is! an! important! requirement! for! tumor!growth!beyond!a! few!millimeters!(Nadkarni,! Geest! et! al.! 2013)! and! thus! a! necessity! for! primary! tumor! growth! as!well!as!metastization.!A!retrospective!study!has!shown!that!high!vessel!counts! in!tumors! of! ovarian! cancer! patients! are! associated! with! a! worse! prognosis! for!
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diseaseLfree! survival! (Hollingsworth,! Kohn! et! al.! 1995).! Moreover,! increased!vascularity! is! associated! with! poor! survival! in! patients! with! ovarian! carcinoma!(Alvarez,! Krigman! et! al.! 1999)! and! with! a! higher! risk! of! recurrence! (Nadkarni,!Geest! et! al.! 2013).! One! mechanism! of! action! in! PG545! is! the! sequestration! of!angiogenic!growth!factors!in!the!extracellular!matrix.!PG545!inhibits!angiogenesis!and!was!previously!found!to!inhibit!angiogenesis!potently!in!an!ex!vivo!rat!aortic!ring!assay!(Dredge,!Hammond!et!al.!2010)!and!in!mouse!models!of!several!types!of!cancer!(Ferro,!Liu!et!al.!2012).!!In!this!study,!we!used!immunohistochemistry!to!analyze!the!microvessel!density!in!the!tumor!specimens.!It!has!to!be!noted,!the!interpretability!of!our!result!is!limited!as!mice!were!sacrificed!at!different!time!points!and!as!the!group!of!mice!receiving!triple! chemotherapy! with! cisplatin,! paclitaxel! and! PG545! followed! by! a! PG545!maintenance! therapy!was!not! included! into! the!analysis!as!only!one!small! tumor!nodule!was!obtained.!!We!found!that!tumors!derived!from!mice!treated!with!PG545,!as!a!firstLline!agent!and! as! a!maintenance! agent,! showed! a! higher!mean! percentage! of! necrotic! area!than!tumors!derived! from!cisplatin!and!paclitaxelLtreated!mice.!Staining!with!the!endothelial!cell!marker!antiL!CD31!showed!reduced!microvessel!density!in!tumors!derived!from!mice!treated!with!PG545!as!a!single!agent,!as!well!as!a!maintenance!agent,! compared! to! tumors! derived! from! untreated!mice! and!mice! treated!with!conventional! primary! chemotherapy.#These! findings! indicate! that!PG545! inhibits!angiogenesis! in! primary! tumor! growth! as! well! as! in! relapsing! tumors,! after!treatment! with! standard! chemotherapy.! Although! the! tumors! of! relapsing! mice!might! be! resistant! to! conventional! chemotherapeutics,! the! decreased!MVD! is! an!indication! that! they! respond! to! PG545! treatment! and! that! the! antiLangiogenic!effect!of!PG545!is!preserved.!!!The!recurrence!of!successfully!treated!ovarian!cancer!has!been!associated!with!the!existence!and!persistence!of!drugL!resistant!cancer!stem!cells!(Binaschi,!Simonelli!et!al.!2011).!Cancer!stem!cells!are!a!small!proportion!of!cells!(0.01%!to!0.1%)!in!a!tumor!that!somewhat!mimics!normal!stem!cell!biology!(Pasquier!and!Rafii!2013).!Cancer! stem! cells! have! the! capacity! to! selfLrenew,! have! unlimited! division!potential,!are!able!to!recapitulate!the!heterogeneity!of!tumors!(Pasquier!and!Rafii!
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2013)!!and!are!highly!tumorigenic!(Cheng,!Ramesh!et!al.!2010).!It!has!been!shown!that! cisplatin! treatment! induces! transition! from! an! epithelial! to! a!mesenchymal!morphology! (epithelial!mesenchymal! transition),! a! process! believed! to! correlate!with!a! ‘cancer!stem!cellL! like’!phenotype!in!residual!cancer!cells!(Latifi,!Abubaker!et!al.!2011).!Moreover,!chemotherapeutical! treatment!of!ovarian!cancer!cell! lines!leads!to!increased!expression!levels!of!cancer!stem!cell!markers!(Abubaker,!Latifi!et!al.!2013).!We!investigated,!in!this!study,!if!chemotherapy!leads!to!changes!in!the!expression!levels!of!the!cancer!stem!cell!markers!BmiL1,!OctL4!and!nanog.!The!aim!was!to!determine!if!PG545!has!the!potency!to!affect!this!cell!population.!!BmiL1! plays! a! role! in! the! selfLrenewal! and! maintenance! of! CSCs! and,! as! an!oncogene,! can! enable! cells! to! escape! apoptosis! (Zhan,! Wang! et! al.! 2013).! OctL4!participates! in!maintenance! of! selfLrenewal! and! pluripotency! in! embryonic! stem!cells.!While!upregulation!of!OctL4!preserves!a!pluripotent!stem!cell!character,!loss!of!OctL4!promotes!differentiation!of!stem!cells!(Samardzija,!Quinn!et!al.!2012).!OctL!4!was!associated!with!tumorigenesis,!when!it!was!first!shown!that!OctL4!increases!the! malignant! potential! of! embryonic! stem! cells! in! a! doseLdependent! manner!(Gidekel,!Pizov!et!al.!2003).!OctL4!expression!was!shown!to!significantly! increase!from!normal!ovarian!surface!epithelium!to!benign!tumors!to!malign!serous!ovarian!cancers,!proposing!the!OctL4!expression!is!associated!with!onset!and!progression!of! serous! ovarian! carcinoma! (Zhang,! Li! et! al.! 2010).! Elevated! levels! of! OctL4! in!tumors!have!been!associated!with!poor!survival!outcome!and!metastasis!(Gidekel,!Pizov! et! al.! 2003).! Nanog! is! another! key! transcription! factor! essential! for!maintaining!stem!cell!properties!such!as!selfLrenewal!and!pluripotency!(Siu,!Wong!et! al.! 2013).! Increased! nanog! expression! has! been! associated! with! highLgrade!cancer,! reduced! chemosensitivity,! proLmetastatic! properties,! and! poor! survival.!Furthermore,! nanog! has! been! shown! to! be! an! independent! prognostic! factor! for!overall!and!diseaseLfree!survival!of!ovarian!cancer!patients!(Siu,!Wong!et!al.!2013).!Our! western! blot! analysis! showed! that! cisplatin! and! paclitaxel! treatment! led! to!enhanced!expression!of!all!three!stem!cell!markers,!compared!to!untreated!tumors.!This! observation! indicates! that! recurrent! tumors,! reLgrowing! after! first—line!chemotherapy! contain! an! increased! percentage! of! tumor! cells! with! cancer! stem!cell!properties!compared!to!untreated!tumors.!In!accordance!with!our!findings,! it!has! been! shown! previously! in! a! colorectal! cancer! in# vivo# mouse# model,! that!
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residual! xenogeneic! tumors! after! chemotherapy! were! enriched! for! cells! with! a!cancer!stem!cell!phenotype!(Dylla,!Beviglia!et!al.!2008).!This!finding!was!expected!as! the! tumor! bulk! was! hypothesized! to! be! more! sensitive! to! chemotherapeutic!agents!than!cells!with!a!cancer!stem!cell!phenotype,!resulting!in!a!higher!frequency!of!these!cells!in!the!residual!tumors!(Dylla,!Beviglia!et!al.!2008).!The!enrichment!of!a!cell!population!with!cancer!stem!cell!characteristics!after!chemotherapy!has!been!reported! in! various!malignancies,! such! as! breast! cancer! (Calcagno,! Salcido! et! al.!2010),! hepatocellular! carcinoma! (Tan,! Chen! et! al.! 2009)! and! lung! cancer.! For!ovarian!cancer,!it!has!been!shown!previously!that!chemotherapeutical!treatment!of!ovarian!cancer!cell!lines!in#vitro!leads!to!increased!expression!levels!of!cancer!stem!cell!markers!(Abubaker,!Latifi!et!al.!2013).!Furthermore,!it!has!been!observed!that!patients! that! have! relapsed! following! initial! chemotherapy! have! a! higher!percentage! of! tumor! cells! with! stemLcell! like! properties! in! their! ascites! than!untreated!ovarian! cancer!patients! (Rizzo,!Hersey! et! al.! 2011).! ! This! is! consistent!with! the! selection! for! tumor! cells! with! stem! cell! like! properties! during!chemotherapy.! Our! finding! indicates! that! compared! to! primary! ovarian! tumors,!tumors!reLgrowing!after! firstLline!chemotherapy!are!enriched!in!tumor!cells!with!cancer!stem!cell!characteristics.!This!might!be!a!consequence!of! the!selection! for!resistant!and!thus!residual!cancer!stem!cells!by!conventional!chemotherapy,!which!initiate!tumor!recurrence.!Tumors!from!mice!treated!with!PG545!expressed!higher!levels!of!bmiL1!and!nanog!and! similar! levels! of! octL4! compared! to! the! control.! This! finding,! although! less!pronounced! than! in! cisplatin/paclitaxel! treated! tumors,! indicates! that! PG545!treatment! leads! to! increased! expression! levels! of! cancer! stem! cell! markers.!Compared! to! cisplatin! and! paclitaxel! treated! tumors,! PG545! treated! tumors!showed!a!tendency!towards!lower!expression!levels,!especially!for!bmiL1!and!octL4.!Hence,!it!is!possible!that!PG545!exhibits!an!effect!even!on!tumor!cells!with!stem!cell! like! properties.! Another! explanation!would! be! that! the! proportion! of! CSC! in!relation!to!other!tumor!cells!is!lower!in!PG545!treated!mice!compared!to!cisplatin!and!paclitaxel!treated!mice.#As!we!have!shown! that!PG545!maintenance! leads! to! inhibition!of! regrowth!after!initial!remission,!we!then!determined!if!PG545!maintenance!might!have!an!effect!on!cancerL! initiating!cells! that!are!most! likely!responsible! for!relapse.!Comparing!
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tumors! of! mice! treated! with! initial! chemotherapy! and! of! mice! additionally!receiving! PG545! as! a! maintenance! agent! showed! a! tendency! for! PG545!maintenance!treatment!to! lead!to!decreased!expression!levels!of!cancer!stem!cell!markers.!The!fact!that!mice!of!both!groups!had!the!same!firstL!line!chemotherapy,!which! led! to! an! enrichment! of! chemoLresistant! cancer! initiating! cells! and! the!finding! that! PG545!maintenance! treated!mice! showed! lower!marker! expression!levels!of!the!CSC!markers!indicates!that!PG545!may!have!the!ability!to!affect!cancer!cells!with!stem!cell!like!properties.!Intensive! research! on! the! microenvironment! of! cancer! stem! cells! led! to! the!identification! of! so! called! stem! cell! niches,! which! play! a! crucial! role! in! the!maintenance! of! stem! cell! characteristics! (Tomao,! Papa! et! al.! 2014).! “Recent!evidence!indicates!that!CSC!live!in!a!“vascular!niche”!that!promotes!their!longLterm!growth! and! selfL! renewal”! (Yi,! Hao! et! al.! 2013).! The! interaction! between! the!‘vascular! niche’! and! CSC! is! highly! complex! and! bidirectional! (Ribatti! 2012).! In!brain! tumors,! it!was! shown! that! endothelial! cells,! as! a! critical! component! of! the!CSC!particular!niche,!supply!secreted!factors!that!maintain!CSC!in!a!stem!cell!state!and!in!turn,!CSC!secrete!high!levels!of!vascular!endothelial!growth!factor!(VEGF),!promoting! the! formation! of! new! blood! vessels! (Ribatti! 2012).! Indeed,! the!significantly!increased!VEGF!expression!of!cancer!stem!cells,!compared!to!normal!tumor!cells,!makes! them!the!most!strongly!angiogenic!cells! in! the! tumor! (Ribatti!2012).!This!strong!proLangiogenic!activity!of!CSC!may!also!play!a!crucial!role!in!the!early!stages!of!growth!and!reLgrowth!after!therapy!(Ribatti!2012).!These!findings!led! to! the! idea! that! therapeutic! targeting! of! the! vascular! could! destroy! the! CSC!niche! microenvironment! and! to! the! attempt! to! target! CSC! via! inhibition! of!angiogenesis! (Calabrese,! Poppleton! et! al.! 2007).! It! was! indeed! shown! that!bevacizumab,! a!VEGF! inhibitor,!was! able! to! reduce! the! stemL! like! cell! fraction! in!brain!tumors!(Calabrese,!Poppleton!et!al.!2007)!(Ribatti!2012)!.!!In!ovarian!cancer,!it!was!shown!that!metformin!decreased!CSC!in#vitro!and!in#vivo!and! inhibited! the! growth! of! ovarian! tumor! spheroids! (Shank,! Yang! et! al.! 2012).!Metformin!treatment!was!also!associated!with!a!decrease!in!microvascular!density!(Pasquier!and!Rafii!2013)!(Shank,!Yang!et!al.!2012).!This!led!to!the!conclusion!that!the!decline!in!CSC!may!lead!to!a!decrease!in!blood!vessel!growth!and!that!the!antiL
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angiogenic! effect! of! metformin! might! be! caused! by! its! antiLCSC! activity! (Shank,!Yang!et!al.!2012).!In! this! study! it!was!not!only!observed! that!PG545! shows!promising!efficacy! in! a!maintenance! setting,!but!also! that!maintenance! treatment!with!PG545! leads! to!a!decrease! in! tumor! vascularity! and! lower! expression! levels! of! cancer! stem! cell!markers,!compared!to!mice!without!maintenance!treatment.!Considering!that!CSC!play! a! crucial! role! in! not! only! tumorLdevelopment,! but! chemoLresistance! and!relapse!after! initial! treatment! (Tomao,!Papa!et! al.! 2014),! further! investigation!of!the!interplay!between!CSC!and!the!microvascular!and!how!PG545!interferes!with!the!two,!might!bring!new!insights!on!the!mechanisms!of!how!the!addition!of!PG545!to! initial! standard! chemotherapy! effectively! prevents! disease! recurrence! and!prolongs!progression!free!and!overall!survival.!!As!angiogenesis!has!also!been!associated!with!ascites!formation!in!ovarian!cancer!!(Gavalas,!Liontos!et!al.!2013),! the!effect!of!PG545!on!malignant!ascites! formation!has! been! assessed! in! an! immunocompetent! ID8L! mouse! model.! Treatment! with!PG545!was!found!to!significantly!reduce!ascites!accumulation.!Reduction!of!ascites!accumulation! has! been! also! observed! in! ovarian! cancer! patients! treated! with!bevacizumab!(Winterhoff,!Freyer!et!al.!2015).!The!formation!of!ascites!is!thought!to!be! caused!by! increased!vascular!permeability! resulting! from!VEGF!expression!(Masoumi!Moghaddam,!Amini!et!al.!2012).! ! It!was!observed!that!plasma!levels!of!VEGF,! HBLEGF,! FGFL2! and! heparanase!were! elevated! in!mice! undergoing! PG545!treatment,!whereas!ascites!VEGF!level!were!reduced.!The!main!factor!of!the!VEGF!level!in!ascites!is!the!secretion!of!VEGF!by!tumour,!stromal!and!immune!cells.!Thus!it! is! likely! that! the! reduced! VEGF! levels! in! ascites! can! be! explained! by! the!suppression!of!one!of!these!cells!(or!a!combination)!under!PG545!treatment.!Pharmacokinetic!studies!revealed!that!AUC!is!the!relevant!measure!of!exposure!to!associate! with! antiLcancer! activity! as! twice–weekly! low! dose! administration!exhibited! similar! effects! to! high! dosing! onceLweekly.! The! dosage! to! achieve!therapeutic! levels! in! patients! was! estimated! to! be! 150!mg! when! applicated! s.c.!(Winterhoff,!Freyer!et!al.!2015).!!
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PG545! is! currently! being! investigated! in! a! Phase! I! clinical! trial! in! patients! with!advanced,! recurrent! solid! cancers.! Four! patients! (with! thyroid! cancer,! colon!cancer,! pancreatic! cancer! and! melanoma)! were! treated! with! once! weekly! s.c.!administration!of!25!or!50!mg!of!PG545.!The!study!was!halted!after! two!to!eight!injections!due!to!unexpected!local!injection!site!reactions.!!Monitoring! of! pharmacodynamic! changes! showed! that! VEGF! plasma! levels!were!elevated!in!patients!during!treatment!with!PG545,!which!is!in!accordance!with!the!findings!of! the! ID8!mouse!model.! Similar! changes!were!observed! in!other! target!proteins!like!FGFL2,!HBLEGF!and!heparanase.!!Elevated!VEGF!plasma!levels,!as!well!as!reduced!VEGF!ascites!levels,!as!seen!under!PG545!treatment,!have!been!previously!reported!for!treatment!with!bevacizumab.!The!elevation!of!these!target!proteins!may!be!the!result!of!blocking!the!interaction!of!VEGF!and!heparanase!with!HS!within!the!tumor!and!as!a!consequence!liberation!of! the! free! ligands! into! the!plasma.!The! rise!of!plasma!VEGF! levels!under!PG545!treatment,! makes! VEGF! a! potential! biomarker! for! drug! response! (Winterhoff,!Freyer!et!al.!2015).!!!In! conclusion,! this! thesis! provides! preclinical! data! to! support! clinical! testing! of!PG545!as!a!novel!antiLcancer!agent!in!patients!with!ovarian!cancer.!!First,! it!was! shown! that! treatment!with! PG545! decreases! cell! viability! of! A2780!and!SKOV3!ovarian!cancer!cells! in!a!dose!dependent!manner! in#vitro.!PG545!was!also!found!to!enhance!cisplatin!and!paclitaxel! induced!cytotoxicity! in#vitro!and!to!have!a!synergistic!effect!in!combination!with!both!drugs.!Moreover,!treatment!with!PG545!decreases!cell!survival!and!potentiates!the!effect!of!cisplatin!in!suspension!culture.!!Our! in#vivo#study! showed,! that! the! addition! of! PG545! to! standard! chemotherapy!and!the!use!of!PG545!as!a!maintenance!agent!prolongs!overall!survival!in!ovarian!cancer!bearing!mice.!Imaging!showed!that!triple!therapy!with!cisplatin,!paclitaxel!and! PG545! followed! by! a! PG545! maintenance! regimen! inhibited! disease!recurrence,! led! to! sustained! disease! remission! and! prolonged! progression! free!survival.!!Immunohistochemistry!of!tumor!specimens!showed!a!reduced!microvessel!density!under!PG545,! as! a! single,! as!well! as! a!maintenance! agent.! CSC!were! found! to! be!
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Background:! ! Despite! ongoing! efforts! to! improve! treatment! strategies,! epithelial!ovarian! cancer! remains! the! leading! cause! of! death! among! gynecologic!malignancies.! In!search!for!new!treatment!options,! there! is!currently!a!particular!focus! on! antiLangiogenic! agents,! such! as! bevacizumab,! which! have! shown!significant!efficacy!benefits! in!clinical!trials.!Nonetheless,!efficacy!remains!limited!due! to! resistance! linked! to! alternative! angiogenic! pathways! and! metastasis.!Therefore,! we! investigated! PG545,! a! novel! heparanLsulfate! mimetic! with! antiLangiogenic! and! antiLmetastatic! properties! using! preclinical! models! of! ovarian!cancer.!!!
Methods:#We!investigated!the!antiLcancer!activity!of!PG545!in#vitro!and!in#vivo#as!a!single! agent! and! in! combination! with! paclitaxel! and! cisplatin.! Furthermore,! we!identified!the!most!effective!treatment!schedule!and!investigated!if!the!addition!of!PG545!to!standard!chemotherapy!can!prevent!disease!recurrence!in#vivo.!
#
Results:#The!in#vitro!experiments!of!this!study!showed!that!treatment!with!PG545!decreases! cell! viability! of! A2780! and! SKOV3! ovarian! cancer! cells,! enhances!cisplatin! and! paclitaxel! induced! cytotoxicity! and! has! a! synergistic! effect! in!combination!with!both!drugs.!Most!importantly,!our!in#vivo#study!showed,!that!the!addition! of! PG545! to! standard! chemotherapy,! and! the! use! of! PG545! as! a!maintenance!agent,! let!to!sustained!disease!remission!and!prolonged!progression!free!and!overall!survival!in!ovarian!cancer!bearing!mice.!Immunohistochemistry!of!tumor!specimens!showed!a!reduced!microvessel!density!under!PG545,!as!a!singleL!as!well!as!a!maintenance!agent.!Maintenance!therapy!with!PG545!led!to!a!reduced!expression! of! CSC! markers! compared! to! primary! chemotherapy! without! a!maintenance!regimen.!!
#





Hintergrund:#!Trotz!fortlaufenden!Bemühungen!die!Therapie!zu!verbessern,!ist!das!epitheliale! Ovarialkarzinom! weiterhin! die! häufigste! Todesursache! unter! den!gynäkologischen! malignen! Erkrankungen.! Bei! der! Suche! nach! neuen!zielgerichteten! Therapeutika! stehen! aktuell! antiLangiogene! Substanzen,! wie!Bevacizumab,! im! Fokus.! Diese! haben! in! klinischen! Studien! bereits! einen!signifikanten!Effektivitätsvorteil!gezeigt.!Dennoch!ist!die!Effektivität!des!gezielten!Angreifens! eines! einzelnen! Signalwegs! durch! Bildung! von! Resistenzen! über!alternative! Signalwege! und! Metastasierung! limitiert.! Daher! haben! wir! in! dieser!Studie!PG545,!ein!neues!HeparansulfatL!Mimetikum!mit!antiLangiogenen!und!antiLmetastatischen! Eigenschaften! ! an! präklinischen! Modellen! des! Ovarialkarzinoms!untersucht.!!
#
Methoden:#In!der!hier!vorgelegten!Dissertation!haben!wir!die!chemotherapeutische!Wirkung! von! PG545! als! Einzelsubstanz! sowie! in! Kombination!mit! Cisplatin! und!Paclitaxel! ! in# vitro! und! in# vivo! untersucht.! ! Wir! haben! den! effektivsten!Behandlungsplan! identifiziert! und! geprüft,! ob! die! Hinzunahme! von! PG545! zur!Standardchemotherapie!Rezidive!verhindern!kann.!!
#
Ergebnisse:#Die!in#vitro!Versuche!dieser!Studie!haben!gezeigt,!dass!die!Behandlung!mit! PG545! das! Zellüberleben! von! A2780! und! SKOV3! Ovarialkarzinomzellen!reduziert,!die!durch!Cisplatin!und!Paclitaxel!induzierte!Zytotoxizität!verstärkt!und!synergistisch!mit!beiden!Medikamenten!wirkt.!Als!bedeutendstes!Ergebnis!dieser!Arbeit! ! haben! die! in# vivo! Studien! gezeigt,! ! dass! die! Ergänzung! von! PG545! zur!Standardchemotherapie! und! der! Einsatz! als! Erhaltungsmedikament! zu! einem!Erhalt! der! Tumorremission! führte! und! das! ! progressionsfreie! und!Gesamtüberleben! in! TumorLtragenden! Mäusen! ! verlängern! konnte.!Immunhistochemische!Analysen!des!Tumorgewebes!zeigten,!dem!antiLangiogenen!Charakter!des!Medikaments!entsprechend,!eine!reduzierte!Mikrogefäßdichte!unter!PG545! Behandlung,! als! EinzelL! sowie! als! Erhaltungsmedikament.! Eine!!Erhaltungstherapie! mit! PG545! führte! zu! einer! reduzierten! Expression! von!
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KrebsstammzellLspezifischen! Markern! verglichen! ! mit! Tumorgewebe,! welches!ausschließlich!mit!ErstlinienLChemotherapie!behandelt!wurde.!
#
Schlussfolgerung:# Zusammenfassend! bietet! diese! Arbeit! weitere! präklinische!Daten,! welche! eine! klinische! Testung! von! PG545! als! neues! onkologisches!Medikament! bei! Patientinnen! mit! fortgeschrittenem! Ovarialkarzinom!unterstützen.!#!!!!!!!!!!!!!!!!!!!!!!!!
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